Cartalax vs KGF-1

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Binds FGFR2b (the KGF receptor), which is exclusively expressed on epithelial cells — providing tissue-specific action without mesenchymal effects. Activates RAS/MAPK and PI3K/Akt to promote keratinocyte proliferation and migration. Extends the anagen phase of the hair growth cycle.

KGF-1 (keratinocyte growth factor 1; FGF-7) is a member of the fibroblast growth factor family that signals exclusively through the FGFR2b splice variant expressed on epithelial cells, where it acts as a potent mitogen and cytoprotective factor for keratinocytes and mucosal epithelial cells; uniquely paracrine in nature, KGF-1 is produced by stromal cells to maintain adjacent epithelial layer integrity and support mucosal healing. KGF-1 activates FGFR2b to drive epithelial cell proliferation, migration, and differentiation, and to protect mucosal surfaces from damage caused by cytotoxic therapies; this cytoprotective mechanism forms the basis of its clinical application in preventing chemotherapy- and radiation-induced breakdown of the gastrointestinal epithelium, where FGFR2b is highly expressed. A landmark randomized controlled trial published in the New England Journal of Medicine (2004) demonstrated that palifermin — recombinant human KGF-1 (Kepivance, Amgen) — significantly reduced the incidence and duration of severe oral mucositis in hematologic malignancy patients undergoing myelotoxic conditioning for stem cell transplant; this pivotal Phase 3 study established the evidence base for FDA approval in 2004. Palifermin (Kepivance) is FDA-approved and requires a prescription for prevention of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy; it is not approved for cosmetic applications, general wound healing, or skin rejuvenation, and the KGF-1 evidence base is specific to chemotherapy-conditioning mucosal protection in oncology settings.